Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...
The company's shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to focus on GLP-1 products.